Advances in rapid detection of SARS-CoV-2 by mass spectrometry

Wong, Tsz-Fung; So, Pui‐Kin; Yao, Zhongping

doi:10.1016/j.trac.2022.116759

Cited by 7 publications

(5 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, various MS‐based testing items have been established in clinics, including newborn screening (Dodds & Baker, 2021; Kilgore et al, 2023), microbe identification (Sandrin & Demirev, 2018; Sauer & Kliem, 2010), and therapeutic drug monitoring (TDM) (Cao et al, 2022; Kim et al, 2021). In the period of the COVID‐19 pandemic, MS was also used for the diagnosis of SARS‐CoV‐2 (Cardozo et al, 2020; Wong et al, 2022; Yoshinari et al, 2022). Despite its outstanding performance in clinical diagnosis and therapy, current clinical MS greatly depends on lab‐scale mass spectrometers typically coupled with gas chromatography (GC) or liquid chromatography (LC) (Maekawa & Mano, 2022; Thomas et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Miniature mass spectrometers and their potential for clinical point‐of‐care analysis

Zhai,

Fu,

2023

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Mass spectrometry (MS) has become a powerful technique for clinical applications with high sensitivity and specificity. Different from conventional MS diagnosis in laboratory, point‐of‐care (POC) analyses in clinics require mass spectrometers and analytical procedures to be friendly for novice users and applicable for on‐site clinical diagnosis. The recent decades have seen the progress in the development of miniature mass spectrometers, providing a promising solution for clinical POC applications. In this review, we report recent advances of miniature mass spectrometers and their exploration in clinical applications, mainly including the rapid analysis of illegal drugs, on‐site monitoring of therapeutic drugs, and detection of biomarkers. With improved analytical performance, miniature mass spectrometers are also expected to apply to more and more clinical applications. Some promising POC analyses that can be performed by miniature mass spectrometers in the future are discussed. Lastly, we also provide our perspectives on the challenges in technical development of miniature mass spectrometers for clinical POC analysis.

show abstract

Section: Introductionmentioning

confidence: 99%

Miniature mass spectrometers and their potential for clinical point‐of‐care analysis

Zhai,

Fu,

2023

Mass Spectrometry Reviews

View full text Add to dashboard Cite

show abstract

“…In the context of the COVID-19 pandemic, rapid and accurate detection of SARS-CoV-2 is critical for preventing infection and interrupting the transmission of SARS-CoV-2. [42] Many detection methods have been developed based on viral nucleic acids, antigens, or viral serology. [43] Due to their high specificity and affinity to target molecules, controllable modification and stable storage, aptamers provide a new strategy for the targeted diagnosis of SARS-CoV-2.…”

Section: Diagnosis and Treatmentmentioning

confidence: 99%

Aptamer‐based strategies against SARS‐CoV‐2 viruses

Huang

Chen

Zhang

et al. 2023

BMEMat

View full text Add to dashboard Cite

The COVID‐19 pandemic, caused by SARS‐CoV‐2, has seriously threatened human life and security in recent years and has had a serious impact on economic development. A range of strategies, including antibodies, small‐molecule agents and vaccines, have been developed and widely used to combat SARS‐CoV‐2. However, the uncertain development and susceptibility to mutation of SARS‐CoV‐2 pose challenges to these approaches, making it necessary to develop a broader range of strategies to complement and expand the diversity of attacks against SARS‐CoV‐2. As promising tools against SARS‐CoV‐2, aptamers have attracted wide attention due to their unique molecular properties. In this review, we survey SARS‐CoV‐2 aptamers and aptamer‐based detection tools as well as aptamer‐based therapeutics. In addition, we analyze the potential value of aptamers in the investigation of SARS‐CoV‐2 infection mechanism and vaccine design. Finally, we look forward to the future development direction of aptamers against SARS‐CoV‐2 or other viruses.

show abstract

“…This makes MS a highly valuable tool for detecting and monitoring the presence of specific virus variants as well as the emergence of new variants [ 9 , 10 ]. The inherent advantages of MS-based assays to detect SARS-CoV-2 infections are their high sensitivity, their speed, the potential to use them in a routine clinical environment, and their cost efficiency per sample [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Development of a rapid and specific MALDI-TOF mass spectrometric assay for SARS-CoV-2 detection

et al. 2023

View full text Add to dashboard Cite

We have developed a rapid and highly specific assay for detecting and monitoring SARS-CoV-2 infections by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). As MALDI-TOF mass spectrometers are available in a clinical setting, our assay has the potential to serve as alternative to the commonly used reverse transcriptase quantitative polymerase chain reaction (RT-qPCR). Sample preparation prior to MALDI-TOF-MS involves the tryptic digestion of SARS-CoV-2 proteins, followed by an enrichment of virus-specific peptides from SARS-CoV-2 nucleoprotein via magnetic antibody beads. Our MALDI-TOF-MS method allows the detection of SARS-CoV-2 nucleoprotein in sample collection medium as low as 8 amol/µl. MALDI-TOF mass spectra are obtained in just a few seconds, which makes our MS-based assay suitable for a high-throughput screening of SARS-CoV-2 in healthcare facilities in addition to PCR. Due to the specific detection of virus peptides, different SARS-CoV-2 variants are readily distinguished from each other. Specifically, we show that our MALDI-TOF-MS assay discriminates SARS-CoV-2 strain B.1.617.2 “delta variant” from all other variants in patients’ samples, making our method highly valuable to monitor the emergence of new virus variants. Graphical Abstract

show abstract

Advances in rapid detection of SARS-CoV-2 by mass spectrometry

Cited by 7 publications

References 66 publications

Miniature mass spectrometers and their potential for clinical point‐of‐care analysis

Miniature mass spectrometers and their potential for clinical point‐of‐care analysis

Aptamer‐based strategies against SARS‐CoV‐2 viruses

Development of a rapid and specific MALDI-TOF mass spectrometric assay for SARS-CoV-2 detection

Contact Info

Product

Resources

About